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Background and Purpose  The aim of this study was to determine the effectiveness of sti-
ripentol (STP) add-on therapy to valproate and clobazam in patients with Dravet syndrome 
(DS) according to the presence of mutations in the sodium channel alpha-1 subunit gene (SC-
N1A).
Methods  We performed direct sequencing to analyze SCN1A mutations in 32 patients with 
clinically confirmed with DS, and classified them into mutation (pathogenic or likely pathogen-
ic) and nonmutation groups based on American College of Medical Genetics and Genomics 
guidelines. We compared the efficacy of STP in reducing the seizure frequency between the two 
groups.
Results  The 32 patients comprised 15 patients in the mutation group (with definite SCN1A 
mutations) and 17 patients in the nonmutation group with variants of unknown significance 
or benign variants. The clinical profile did not differ significantly between the mutation and 
nonmutation groups. The seizure frequency relative to baseline reduced by 72.53±23.00% 
(mean±SD) in the mutation group versus 50.58±40.14% in the nonmutation group (p= 
0.004). The efficacy of STP was better in DS patients with missense mutations that in those 
with truncation mutations, and was not favorable in patients with mutations at linkers between 
domains (DII–DIII), linkers between segments of domain I (DI S1–S2), or splice sites, although 
the small number of patients prevented statistical analyses.
Conclusions  The efficacy of STP was significantly better in DS patients with definite SCN1A 
mutations than in those without mutations.
Key Words   Dravet syndrome, SCN1A, sodium channel alpha-1 subunit, stiripentol. 
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INTRODUCTION
Dravet syndrome (DS) is one of the most intractable epileptic encephalopathies, and it is 
characterized by febrile seizures beginning in the first year of life, multiple seizure types, and 
psychomotor function regression.1,2 About 70% of DS patients are known to carry muta-
tions in the sodium channel alpha-1 subunit gene (SCN1A).3-5 It has been revealed that 
malfunction of inhibitory neurons underlies the brain hyperexcitability evident in epilepsy 
patients with SCN1A mutations.6 
Stiripentol (STP) at clinically relevant concentrations enhances central GABA neuro-
transmission by increasing the duration of GABA-A receptor channel opening and inter-
feres with GABA reuptake and metabolism.7-9 STP was approved for DS as an orphan drug 
throughout Europe and other countries in the early 2000s, and it is still the only drug spe-
cifically indicated for DS in combination with valproate and clobazam.10 Previous studies 
have found that this combination shows short-term efficacy in reducing the frequency and 
duration of seizures.
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However, the etiology of DS remains unknown in about 
20% of DS patients, and additional genes including GABRG2 
and SCN1B are probably implicated.11 In the present study, 
we therefore aimed to determine the efficacy of STP in con-
trolling seizures according to the presence of definite SCN1A 
mutations in patients with DS.
 
METHODS
Patients and stiripentol efficacy assessments
In total, 32 unrelated pediatric patients were clinically diag-
nosed with typical DS at Severance Children’s Hospital from 
January 2007 to May 2015. All of these patients met the fol-
lowing criteria:1,2 1) prolonged febrile and nonfebrile sei-
zures within the first year of a life, 2) many different seizure 
types including myoclonic seizures, 3) frequent seizures when 
ill or having a fever during childhood, and 4) normal devel-
opment in the early years followed by progressive develop-
mental delay. 
In accordance with known guidelines,9,10 STP was intro-
duced at a dosage of 25 mg/kg/day, with an ultimate target 
dosage of 100 mg/kg/day over 4 weeks. When a side effect 
occurred, the STP dosage was increased more slowly or ad-
justed in some other way so as to minimize the side effect. The 
occurrence of any drug interactions resulted in the maximum 
dosages of valproate and clobazam being decreased to 20 and 
0.5 mg/kg/day, respectively.
Thirty-two patients were classified into a mutation group 
with pathogenic/likely pathogenic variants (n=15) and a 
nonmutation group with variants of unknown significance 
(VOUS) or benign variants (n=17). All patients were fol-
lowed up on a monthly basis, with information obtained us-
ing medical records and seizure diaries, and missing data col-
lected by telephone calls. The baseline seizure frequency was 
obtained from the total number of all clinical seizures that 
occurred during the 12-week period preceding STP medi-
cation. The efficacy was assessed by comparing the baseline 
seizure frequency with that observed during the final 12 
weeks before the last visit. The efficacy of STP in seizure con-
trol was compared between the two groups using the mean 
percentage reduction from the baseline seizure frequency as 
an exploratory efficacy variable. We also examined the effica-
cy of STP in patients according to the type of mutation (trun-
cation or missense) and the protein location of the mutation.
In statistical analyses, independent t-tests were used to com-
pare data between the mutation group (pathogenic and 
likely pathogenic) and the nonmutation group (VOUS and 
benign). Two-sided Fisher exact tests and Pearson’s chi-square 
tests were also applied. PASW statistics software (version 
18.0, SPSS Inc., Chicago, IL, USA) was used to implement 
the statistical analyses, and p values <0.05 were considered 
statistically significant.
SCN1A analysis and interpretation of variants
Direct sequencing of all coding exons and flanking intron 
sequences of SCN1A was performed using primer pairs de-
signed by the authors. Sequence variations were analyzed 
by comparison with the corresponding wild-type sequence. 
When pathogenic or likely pathogenic variants were con-
sistent with the patient’s phenotype, final validation using 
another type of confirmatory assay and a parental study 
was planned. The variants were interpreted in accordance 
with the five-tier classification system recommended by the 
American College of Medical Genetics and Genomics/As-
sociation for Molecular Pathology (ACMG/AMP) using a 
step-by-step approach. VOUS (and especially missense vari-
ants) were prioritized according to population frequency, 
ACMG/AMP score, and the patient’s clinical phenotype.12 
Parental studies were scheduled to detect de novo occur-
rence. For patients without mutations, the presence of copy-
number variations including large exon deletions and dupli-
cations was confirmed by multiplex ligation-dependent 
probe amplification (MLPA) using the SALSA MLPA P245 
Microdeletion Syndrome kit for SCN1A (MRC Holland, 
Amsterdam, the Netherlands).
The study protocol was approved by the Institutional Re-
view Board of Yonsei National University Hospital (IRB No. 
4-2016-0921). Written informed consent was obtained from 
the parents of all enrolled patients.
 
RESUlTS
Patient demographics 
The 32 patients enrolled in this study comprised 13 males 
and 19 females with an age at seizure onset of 7.08±6.84 
months (mean±SD; range 3.0–15.0 months). Their age at the 
initiation of STP medication was 73.08±51.48 months (range 
12.0–192.0 months), their STP dosage was 42.73±17.06 mg/
kg/day, and their medication duration was 34.44±144.0 months 
(range 3.0–81.0 months). We also compared the baseline 
characteristics between the mutation group (pathogenic or 
likely pathogenic variants) and nonmutation group. The STP 
dose did not differ significantly between the mutation group 
(44.80±16.20 mg/kg/day) and nonmutation group (40.91± 
18.08 mg/kg/day) (p=0.527), nor did any of the other clini-
cal characteristics. The clinical and demographic profiles of 
the patients are summarized in Table 1.
SCN1A mutations
SCN1A analysis revealed pathogenic or likely pathogenic 
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variants in 15 patients, comprising 10 truncations (5 nonsense 
mutations and 5 frameshift mutations), 4 missense mutations, 
and 1 splice-site mutation. The detailed genotypes are pre-
sented in Table 2. VOUS were present in eight patients, while 
nine patients had benign variants (Table 3). The locations of 
pathogenic and likely pathogenic variants were defined using 
a website (http://www.uniprot.org) showing gene locations 
(Table 2 and Fig. 1). Mutations were present at S1–S2 loop 
segments in three patients, at S5–S6 pore-loop segments in 
two patients, at linkers between domains in two patients, at the 
C-terminal in two patients, at the fourth transmembrane seg-
ment (S4) in two patients, and at other transmembrane seg-
ments in four patients. 
Response to stiripentol according to SCN1A 
mutations
The seizure frequency reduced by 72.53±23.00% in the 
mutation group versus 50.58±40.14% in the nonmutation 
group (p=0.004) (Fig. 2). The efficacy of STP could unfortu-
nately not be analyzed statistically according to mutation type 
or site in DS patients with mutations due to the small num-
ber of patients in each group (Table 2). Nonetheless, we did 
find the following characteristic tendencies: The seizure fre-
quency reduced by 70.50±22.32% in 10 patients with trunca-
tion mutations and by 87.50±11.90% in 4 patients with mis-
sense mutations. In addition, according to the mutation site, 
STP was intriguingly 100% effective for two mutations in the 
voltage sensor segment (S4) and another segment (S3), while 
it did not exhibit favorable efficacy in three patients with 
mutations located at linkers between domains (DII–DIII), 
Table 1. Patient characteristics according to the presence of SCN1A mutations
Mutation No mutation p
Gender (female/male) 11/4 8/9 0.131
Age at seizure onset (years) 0.44±0.19 0.72±0.75 0.166
Age when diagnosed with DS (years) 4.00±3.76 4.11±4.02 0.933
Age at STP medication initiation (years) 6.06±3.88 6.11±4.74 0.974
Dose of STP (mg/kg/day) 44.80±16.20 40.91±18.08 0.527
Data are n or mean±SD values.
DS: Dravet syndrome, SCN1A: sodium channel alpha-1 subunit gene, STP: stiripentol.
Table 2. SCN1A mutational analysis in the mutation group
Patient 
no.
Nucleotide change
Amino acid 
change
ACMG/AMP 
classification
Mutation type
Protein 
location
STP response 
(%)*
Truncation mutations
1    c.3733C>T p.R1245X P Nonsense DIII S1–S2 75
2    c.3633T>A p.C1211X LP Nonsense DII–DIII 33
3    c.4933C>T p.R1645X LP Nonsense DIV S4 100
4    c.4219C>T p.R1407X P Nonsense DIII S5–S6 75
5    c.459G>A p.W153X LP Nonsense DI S1–S2 80
6    c.3576_3580delTCAAA p.I1194CfsX21 LP Frameshift DII–DIII 70
7    c.5536_5539del p.K1846SfsX11 P Frameshift C-terminal 84
8    c.596_602+3delCATTTGCGTA p.T199SfsX15 LP Frameshift DI S1–S2 38
9    c.5390delC p.A1797EfsX4 LP Frameshift C-terminal 95
10    c.408delinsGA p.C136WfsX14 LP Frameshift DI S1 55
Missense mutations
11    c.580G>A p.D194N LP Missense DI S3 100
12    c.580G>A p.D194N LP Missense DI S3 95
13    c.5341T>C p.Y1781H LP Missense DIV S6 75
14    c.4261G>T p.Gly1421Trp LP Missense DIII S5–S6 80
Splice-site mutation
15    c.2415+1G>A LP Splice site 33
*Mean percentage reduction relative to the baseline seizure frequency.
ACMG/AMP: American College of Medical Genetics and Genomics/Association for Molecular Pathology, D: domain, LP: likely pathogenic, P: pathogen-
ic, S: segment, SCN1A: sodium channel alpha-1 subunit gene, STP: stiripentol.
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linkers between segments of domain I (DI S1–S2), or splice 
sites. Moreover, the efficacy of STP was similar regardless of 
the mutation site of SCN1A. 
With regard to side effects of STP, two patients reported 
feeling sedated even after the STP dosages had been adjust-
ed, and one patient experienced loss of appetite. No major 
side effects or adverse events were observed.
DISCUSSION
We have compared the efficacy of STP between patients with 
pathogenic or likely pathogenic variants of SCN1A and those 
with VOUS or benign variants of SCN1A. STP combined 
with valproate and clobazam significantly reduced the seizure 
frequency in patients with DS due to definite SCN1A muta-
tions.
DS provokes a devastating epileptic encephalopathy, and 
affected patients present with cognitive impairment, autistic 
Table 3. SCN1A mutational analysis of the nonmutation group 
Patient 
no.
Nucleotide change Amino acid change ACMG/AMP classification Protein location STP response (%)*
16 c.4168G>A p.V1390M VOUS DIII S5–S6 0
17 c.1279G>A p.G427L VOUS DI–DII54 0
c.3515A>C p.E1172A VOUS DII–DIII 0
18 c.1279G>A p.G427L VOUS DI–DII 97
19 c.1279G>A p.G427L VOUS DI–DII 0
c.3515A>C p.E1172A VOUS DII–DIII 0
20 c.4778T>A p.I1593N VOUS DIV S2 66
21 c.818T>A p.L273Q VOUS DI S5 50
22 c.1069A>T p.N357Y VOUS DI S5–S6 95
23 c.4133A>C p.N1378T VOUS DIII S5–S6 100
24 c.383+66T>C Benign 30
c.965-21C>T Benign 30
c.1028+21T>C Benign 30
c.1029-68C>T Benign 30
c.1377+52G>A Benign 30
c.1663-47T>G Benign 30
c.2292T>C p.V764= Benign DII S1 30
c.3199A>G p.A1067T Benign DII–DIII 30
25 c.383+64A>G Benign 86
c.1170+75C>A Benign 86
c.1028+21T>C Benign 86
c.1212A>G p.V404= Benign DI S6 86
26 c.1028+21T>C Benign 60
c.1029-47T>G Benign 60
c.1212A>G p.V404= Benign DI S6 60
c.2292T>C p.V764= Benign DII S1 60
27 c.1212A>G p.V404= Benign DI S6 95
c.2292T>C p.V764= Benign DII S1 95
28 c.1170+75C>A Benign 0
29 c.1028+21T>C Benign 25
c.1170+75C>A Benign 25
30 c.1170+75C>A Benign 0
31 c.1170+75C>A Benign 90
32 c.1028+21T>C Benign 66
c.1170+75C>A Benign 66
*Mean percentage reduction relative to the baseline seizure frequency.
D: domain, S: segment, SCN1A: sodium channel alpha-1 subunit gene, STP: stiripentol, VOUS: variants of unknown significance.
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behavior, and psychiatric disorders.1,2 De novo heterozygous 
mutations in SCN1A, which encodes a subunit of the neuro-
nal voltage-gated sodium channel Nav1.1, result in faulty so-
dium channels in more than 70% of DS patients. SCN1A is a 
widely investigated gene due to its involvement in epilepsy 
and other neuronal disorders, and its expression in specific 
types of neurons and its role in the generation of action po-
tentials have been studied intensively. The effects of SCN1A 
mutations on epilepsy have been revealed using SCN1A-spe-
cific knock-out or knock-in mice and a DS-specific repro-
gramming stem cell model, with the results indicating that 
the malfunction of inhibitory neurons is related to brain hy-
perexcitability.6 
Based on the pathogenesis of DS, certain antiepileptic 
drugs (AEDs) including carbamazepine, oxcarbazepine, la-
motrigine, and phenytoin should be avoided since they can 
aggravate seizures.13,14 Conversely, drugs that enhance GAB-
Aergic neuron function including valproate, clobazam, and 
STP hold promise in controlling intractable seizures in pa-
tients with DS. Combining STP with valproate and clobazam 
may therefore be particularly effective in reducing the seizure 
frequency. 
STP is a new-generation AED that enhances GABAergic 
transmission, and was first used to treat DS in the early 2000s.14 
STP augments GABAergic activity by extending the mean 
open time of GABA-A receptors and increases GABA levels 
by interfering with its reuptake by acting as a positive allo-
steric modulator of these receptors. STP also inhibits lactate 
dehydrogenase, an enzyme that increases neuron activity by 
stimulating ATP-sensitive potassium channels. In addition, 
STP increases the concentration and duration of an AED by 
inhibiting cytochrome P450 enzymes.7-9 Many previous stud-
ies found that the seizure frequency was significantly lower 
for STP than in placebos.14-22 Inoue et al.15-17 conducted an 
open-label multicenter study and found that STP was an ef-
fective add-on therapy to reduce the seizure frequency in Jap-
anese patients with DS. Chiron et al.18 conducted a random-
ized, double-blinded, placebo-controlled trial of add-on STP 
therapy in 41 patients with DS, and found 71% responders in 
the STP group compared to 5% responders in the placebo 
group. De Liso et al.22 investigated the efficacy of the STP in a 
cross-sectional study, and found that STP add-on therapy re-
duced the seizure frequency and severity in DS. However, 
none of these studies classified the effect of STP according to 
SCN1A mutation, since all patients with DS were included ir-
respective of whether or not they had a mutation. In contrast, 
the present study compared the efficacy of STP in the presence 
or absence of SCN1A mutations in patients with DS, with the 
results showing that STP was more effective in patients with 
Fig. 1. Protein locations of sodium channel alpha-1 subunit gene (SCN1A) mutations.
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Fig. 2. Efficacy of stiripentol according to the presence of SCN1A mu-
tations. *p=0.004. SCN1A: sodium channel alpha-1 subunit gene.
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definite SCN1A mutations.
SCN1A consists of four domains (DI–DIV), six transmem-
brane segments (S1–S6) including voltage sensor (S4) and 
pore-loop (S5–S6) regions, and connecting cytoplasmic loops 
or linkers.4,5 Ishii et al.23 reported that truncation mutations 
were distributed throughout the SCN1A protein in Japanese 
DS patients with mutations affecting particular regions within 
the channel, with half of missense mutations being in the pore 
region. We also demonstrated that truncation mutations are 
distributed more randomly in specific areas of the sodium 
channel. Ishii et al.23 also examined the response to AEDs as 
an add-on therapy according to the SCN1A mutation type 
(truncation or missense variants), and found that the most 
effective AEDs in patients with truncation mutations were 
STP, topiramate, and bromide (in decreasing order of efficacy), 
whereas the most effective AEDs in patients carrying mis-
sense mutations were clonazepam, bromide, and topiramate 
(also in decreasing order of efficacy). In contrast to a previous 
report,23 we found that efficacy of STP was somewhat better 
in patients with missense mutations than in those with trun-
cation mutations; however, the small number of patients 
with missense mutations meant that statistical analysis could 
unfortunately not be performed. Nonetheless, we can suggest 
that STP is effective even in missense mutations if these mu-
tations cause changes in the structure of sodium channels 
that contribute to pathogenesis. We also investigated whether 
STP was more effective in patients with mutations at specific 
locations, but failed to find any significant differences. One 
particularly notable finding was that seizures were poorly con-
trolled in patients with SCN1A mutations at linkers between 
segments or domains other than in the pore-forming region. 
These results might be related to pathomechanisms of inhibi-
tory neurons, but further research is required to elucidate the 
underlying electrophysiologic mechanisms in detail.
This study was subject to some limitations, including the 
relative smallness of the sample and it being designed as a 
retrospective review of clinical data. Nonetheless, we were able 
to demonstrate that STP has better efficacy in DS patients 
with definite SCN1A mutations than in DS patients with 
VOUS and benign SCN1A mutations. Further comparative 
prospective studies with larger samples are needed to deter-
mine the efficacy of STP according to the presence of SCN1A 
mutations. 
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